Search research articles
Contact Us
Filters
Showing results (11-20 of 29) with videos related to
Page
of 3
Sort By:
Cancer Research
|
August 1, 1991
Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon
L M Weiner, K Padavic-Shaller, J Kitson, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
April 1, 1995
Phase I study of sequentially administered recombinant tumor necrosis factor and recombinant interleukin-2
R L Krigel, K Padavic-Shaller, C Toomey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1994
Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer
R L Krigel, C S Palackdharry, K Padavic, et al.
Journal of Biological Response Modifiers
|
August 1, 1989
Exacerbation of epidemic Kaposi's sarcoma with a combination of interleukin-2 and beta-interferon: results of a phase 2 study
R L Krigel, K A Padavic-Shaller, A R Rudolph, et al.
Urology
|
August 1, 1992
Hoarseness; a unique clinical presentation for renal cell carcinoma
R E Greenberg, J Cooper, R L Krigel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1990
Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon
R L Krigel, K A Padavic-Shaller, A R Rudolph, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 15, 1995
Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy?
B P O'Neill, J R O'Fallon, J D Earle, et al.
Cancer Research
|
July 1, 1988
A phase I study of recombinant interleukin 2 plus recombinant beta-interferon
R L Krigel, K A Padavic-Shaller, A R Rudolph, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 1984
Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine
L J Laubenstein, R L Krigel, C M Odajnyk, et al.
Journal of the National Cancer Institute
|
January 16, 1991
Hemorrhagic gastritis as a new dose-limiting toxicity of recombinant tumor necrosis factor
R L Krigel, K A Padavic-Shaller, A A Rudolph, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 29) with videos related to
Sort By:
Page
of 3
Cancer Research
|
August 1, 1991
Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon
L M Weiner, K Padavic-Shaller, J Kitson, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
April 1, 1995
Phase I study of sequentially administered recombinant tumor necrosis factor and recombinant interleukin-2
R L Krigel, K Padavic-Shaller, C Toomey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1994
Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer
R L Krigel, C S Palackdharry, K Padavic, et al.
Journal of Biological Response Modifiers
|
August 1, 1989
Exacerbation of epidemic Kaposi's sarcoma with a combination of interleukin-2 and beta-interferon: results of a phase 2 study
R L Krigel, K A Padavic-Shaller, A R Rudolph, et al.
Urology
|
August 1, 1992
Hoarseness; a unique clinical presentation for renal cell carcinoma
R E Greenberg, J Cooper, R L Krigel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1990
Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon
R L Krigel, K A Padavic-Shaller, A R Rudolph, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 15, 1995
Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy?
B P O'Neill, J R O'Fallon, J D Earle, et al.
Cancer Research
|
July 1, 1988
A phase I study of recombinant interleukin 2 plus recombinant beta-interferon
R L Krigel, K A Padavic-Shaller, A R Rudolph, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 1984
Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine
L J Laubenstein, R L Krigel, C M Odajnyk, et al.
Journal of the National Cancer Institute
|
January 16, 1991
Hemorrhagic gastritis as a new dose-limiting toxicity of recombinant tumor necrosis factor
R L Krigel, K A Padavic-Shaller, A A Rudolph, et al.
Page
of 3